Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INSULET CORPORATION

(PODD)
  Report
Delayed Quote. Delayed Nasdaq - 12/02 04:00:01 pm
287.24 USD   +1.33%
11/25Insulet to Present at Nasdaq's 45th Investor Conference
AQ
11/24Insulet to Present at Nasdaq's 45th Investor Conference
BU
11/15INSIDER SELL : Insulet
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insulet’S Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control with One Year of Use

09/30/2021 | 07:30am EST

Insulet Corporation has presented positive pivotal trial extension phase results for the Omnipod® 5 Automated Insulin Delivery System (Omnipod 5). Omnipod 5, the world’s first tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children, adolescents, and adults, aged 6-70 years, with type 1 diabetes over a period of 12 months. The data was presented at EASD 2021, the annual meeting of the European Association for the Study of Diabetes. Insulet also presented new clinical outcomes data for people with type 1 diabetes using the Omnipod DASH® System (Omnipod DASH) for 90 days, as well as overall positive self-management behaviors among individuals using Omnipod DASH, Continuous Glucose Monitoring (CGM) and a cloud-based diabetes data management system. Following completion of the 3-month pivotal trial, the results of which were previously shared, 95% of study participants chose to continue use of Omnipod 5 in an ongoing extension study. Insulet presented its data in two groups of extension study participants with type 1 diabetes: 114 adults and adolescents between 14 and 70 years old, and 110 children aged 6 to 13.9 years. The participants used Omnipod 5 at home for a period of 12 months after a 14-day period using their standard therapy, which included both pump therapy and multiple daily injections. The results were presented in 3-month intervals: months 1-3 (the pivotal study), months 4-6, months 7-9, and months 10-12. After 3 months of system use, adults and adolescents had a decrease in HbA1c from 7.2% to 6.8%. This decrease was maintained after a total of 12 months of use, with mean HbA1c remaining at 6.8%. Time in range (TIR) increased from 63.6% to 73.8% in the first 3 months of use, and persisted at 72.7% in months 10-12 of use, corresponding to an additional 2.3 hours in target range. Median time


© S&P Capital IQ 2021
All news about INSULET CORPORATION
11/25Insulet to Present at Nasdaq's 45th Investor Conference
AQ
11/24Insulet to Present at Nasdaq's 45th Investor Conference
BU
11/15INSIDER SELL : Insulet
MT
11/08Raymond James Adjusts Price Target on Insulet to $329 from $285, Keeps Outperform Ratin..
MT
11/08UBS Lifts Insulet's Price Target to $325 From $267 on Sales Estimates; Neutral Rating K..
MT
11/08Berenberg Bank Adjusts Insulet's Price Target to $295 From $277, Maintains Hold Rating
MT
11/05SVB Leerink Adjusts Price Target on Insulet to $350 from $300, Keeps Outperform Rating
MT
11/05INSULET CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/04Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year - Form 8-K
PU
11/04Insulet Posts Q3 EPS Gain Short of Street View as Revenue Rises, Lifts Low End of 2021 ..
MT
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 092 M - -
Net income 2021 15,6 M - -
Net Debt 2021 347 M - -
P/E ratio 2021 1 223x
Yield 2021 -
Capitalization 19 810 M 19 810 M -
EV / Sales 2021 18,5x
EV / Sales 2022 15,6x
Nbr of Employees 1 900
Free-Float 99,5%
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 287,24 $
Average target price 309,65 $
Spread / Average Target 7,80%
EPS Revisions
Managers and Directors
Shacey Petrovic President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION10.89%19 549
ABBOTT LABORATORIES14.87%224 113
MEDTRONIC PLC-8.91%141 843
BECTON, DICKINSON AND COMPANY-5.23%68 640
HOYA CORPORATION24.39%59 332
DEXCOM, INC.48.31%53 147